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Abstract
The production, manipulation and rescue of a bacterial artificial chromosome clone of Vaccinia virus (VAC-BAC) in order to
expedite construction of expression vectors and mutagenesis of the genome has been described (Domi & Moss, 2002, PNAS
99 12415–20). The genomic BAC clone was ‘rescued’ back to infectious virus using a Fowlpox virus helper to supply
transcriptional machinery. We apply here a similar approach to the attenuated strain Modified Vaccinia virus Ankara (MVA),
now widely used as a safe non-replicating recombinant vaccine vector in mammals, including humans. Four apparently full-
length, rescuable clones were obtained, which had indistinguishable immunogenicity in mice. One clone was shotgun
sequenced and found to be identical to the parent. We employed GalK recombination-mediated genetic engineering
(recombineering) of MVA-BAC to delete five selected viral genes. Deletion of C12L, A44L, A46R or B7R did not significantly
affect CD8
+ T cell immunogenicity in BALB/c mice, but deletion of B15R enhanced specific CD8
+ T cell responses to one of
two endogenous viral epitopes (from the E2 and F2 proteins), in accordance with published work (Staib et al., 2005, J. Gen.
Virol. 86, 1997–2006). In addition, we found a higher frequency of triple-positive IFN-c, TNF-a and IL-2 secreting E3-specific
CD8+ T-cells 8 weeks after vaccination with MVA lacking B15R. Furthermore, a recombinant vaccine capable of inducing
CD8
+ T cells against an epitope from Plasmodium berghei was created using GalK counterselection to insert an antigen
expression cassette lacking a tandem marker gene into the traditional thymidine kinase locus of MVA-BAC. MVA continues
to feature prominently in clinical trials of recombinant vaccines against diseases such as HIV-AIDS, malaria and tuberculosis.
Here we demonstrate in proof-of-concept experiments that MVA-BAC recombineering is a viable route to more rapid and
efficient generation of new candidate mutant and recombinant vaccines based on a clinically deployable viral vector.
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Introduction
Modified Vaccinia virus Ankara (MVA) is a replication-deficient
attenuated poxvirus that was derived from Vaccinia virus by Mayr
et al. through more than 500 blind passages in chick embryo
fibroblast (CEF) cell culture [1]. With the notable exception of the
Syrian hamster cell line BHK-21 [2], MVA is unable to replicate
productively in mammalian cells, though genome replication, late
gene expression and immature virion formation usually occur
[3,4]. During its attenuation, MVA acquired large genomic
deletions totalling about 30 kb, resulting in the complete loss of 26
open reading frames (ORFs), together with truncation or
fragmentation of a further 21 ORFs and numerous smaller scale
mutations [5]. MVA does not therefore express many of the
known poxviral immune evasion and virulence factors [6–8],
though how this determines its abortive phenotype in mammalian
cells is not well understood [9]. Despite these features, MVA is at
least as immunogenic as conventional replicating Vaccinia virus
[10–13] and has the advantage of a considerably improved safety
profile [14].
Attention has focussed on MVA not only as a possible ‘next
generation’ smallpox vaccine [15–17], but also as a recombinant
vaccine vector, with particular value in combination with other
vectors (e.g. DNA, adenovirus, or an avian poxvirus) as a component
of heterologous prime-boost regimens designed to elicit high
frequencies of antigen-specific T cells [18]. This approach is
undergoing development and clinical trial for diseases such as HIV-
AIDS [19,20], tuberculosis [21,22] and malaria [23,24], where
protective T cell responses are required for vaccine efficacy. In the
case of liver-stage malaria vaccines, specific cytotoxic T cell responses
correlate with the limited levels of protection achieved so far in
humans [25], but current vectors and regimens are not immunogenic
enough to achieve significant efficacy in malarious regions [26].
There is therefore a need to identify recombinant vaccine vectors
with greater immunogenicity, either by using novel vectors (e.g.
simian adenoviruses [27]) or by improving existing platforms.
The routes available for attempts to improve MVA vector
immunogenicity can be crudely divided into addition or removal
of genes. Co-expression of costimulatory molecules, such as B7.1
[28] and 4-1BB ligand [29] and various cytokines, including IL-12
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recombinant poxvirus vaccine immunogenicity. These interven-
tions can achieve a two- to four-fold increase in peak murine IFN-
c T cell responses. The parallel strategy is to delete poxviral genes
encoding immunomodulators that attenuate adaptive immune
responses, but are not required for growth in vitro. During
attenuation MVA lost many such factors, including soluble decoy
receptors for IFN-c [33], TNF-a [34], IFN-a/b [35] and various
chemokines [36]; an inhibitor of IL-1b converting enzyme [37],
the complement control protein [38] and an intracellular inhibitor
of Toll-like receptor (TLR) and IL-1 receptor (IL-1R) signalling
[39]. On the other hand, it retains genes encoding secreted
interleukin- [40–42] and chemokine- [36,43] binding proteins; a
dehydrogenase involved in steroid synthesis [44,45], a second
inhibitor of TLR/IL-1 receptor signalling [46], and other genes
implicated in poxviral virulence [47–50]. Evidence that deletion of
such genes provides a route for improvement of MVA immuno-
genicity is provided by reports of augmented protective mouse
CD8
+ T cell responses elicited by MVA lacking B15R, encoding
an IL-1b binding protein [51], and A41L, encoding a chemokine
binding protein of unknown specificity [43].
In addition to ap r i o r icandidates, there are at least 30 MVA genes
whose function remains unknown. Although many poxviral proteins
retain sequence homology and functional similarity with host
proteins, it has recently been shown in the case of Vaccinia virus
protein N1 that preservation of structure and function can occur in
the absence of significant sequence similarity [52]. An unbiased
experimental approach is therefore required for identification of
MVA genes that negatively affect its immunogenicity. In order to
expedite this approach, we have constructed a bacterial artificial
chromosome (BAC) clone of the MVA genome using the elegant
method devised by A. Domi and B. Moss for Vaccinia virus [53],
with slight modifications. Recombination-mediated genetic engi-
neering (recombineering) of this construct [54,55] permits more
rapid generation of mutants for analysis than can be achieved by
traditional methods, with the possible exception of host-range
selection on rabbit cells using K1L [56,57]. To test this concept, we
deleted five MVA genes using recombineering of a fully sequenced
BAC clone, rescued the constructs to infectious virus, and here
demonstrate a modest but significant improvement in immunoge-
nicity of MVA lacking B15R, supporting and extending published
work [51]. For large-scale biomanufacturing of an MVA-based
vaccine for clinical use,the ability to use clonal purifed BAC DNA as
the starting-point, rather than a conventional plaque-purified
recombinant, is likely to be of considerable value. With this aim in
mind,aswellaspre-clinicalstudies,we demonstrate immunogenicity
of a recombinant antigen inserted at the traditional thymidine kinase
locus of MVA-BAC by recombineering.
Materials and Methods
Recombinant MVA construction
Figure 1 shows the plasmid construct used to generate a
recombinant virus (referred to as MVA-BAC-parent) containing
the entire sequence of the BAC vector pBELO-BAC11 at the
Deletion III locus of MVA (between the remnants of A51R and
A56R) together with a GFP reporter gene driven by the p4B late
promoter from Fowlpox virus. The fragments required were
amplified by PCR with primers designed to introduce restriction
sites for assembly by standard methods. The flanking regions for
recombination correspond to positions 148412-149083 and
149340-149855 of MVA genome sequence U94848 [5]. The
plasmid was linearised with PacI and transfected into MVA-
infected primary chick embryo fibroblast (CEF) cells (Institute for
Animal Health, Compton, UK). The cells were trypsinised and
GFP-positive cells were sorted by flow cytometry on a Dako
Cytomation MoFlo prior to plaque picking of the recombinant
virus to purity, amplification and titration on CEFs. Cells were
maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% FCS or with 2% FCS for viral growth.
Identity and purity were confirmed by PCR. MVA expressing the
recombinant antigen TIP was prepared as described (A. Spencer et
al., manuscript in preparation).
Generation of MVA-BAC
CEF cells in 6-well plates were infected with MVA-BAC-parent
at 5 pfu/cell and 2 h later the inoculum was replaced with growth
medium containing 45 mM isatin-b-thiosemicarbazone (IbT). The
compound was kindly synthesised by Dr J. Robertson (Chemistry
Research Laboratory, Oxford University) and was dissolved to
5 mg/mL in acetone for storage at 220uC, then diluted to 1mg/
mL in 0.25 M NaOH immediately prior to use. The cells in some
wells were transfected with pCI-Cre (obtained from A. Domi,
NIAID, NIH, Bethesda, MD) using Lipofectamine (Invitrogen).
The DNA was phenol-extracted from the cultures 24h later as
described [53] and resuspended in 20 ml of Tris-EDTA. Of this
material, 3 ml was electroporated into DH10B E. coli (Invitrogen)
prior to selection on LB plates with chloramphenicol (12.5 mg/
mL) and miniprep by alkaline lysis from liquid LB cultures. Clones
were screened by PCR for the presence of the genes MVA005,
MVA010, MVA044, MVA086 and MVA188. For restriction
mapping and pulsed-field gel electrophoresis, BAC DNA was
prepped by QIAgen kit and 0.5–1 mg of DNA was digested
overnight in a 15 ml reaction with the relevant enzymes (NEB).
MVA-BAC clone 26 was shotgun sequenced at eightfold coverage
by Lark Technologies (Cogenics), Inc.
BAC rescue
BHK-21 cells (maintained in DMEM+10% FCS) were seeded
into 6-well plates and infected with FP9-LacZ [58], an attenuated
strain of Fowlpox virus expressing b-galactosidase, at 1 pfu/cell in
Optimem (Gibco). After 1–2 hours, the cells were transfected with
4 mg of Qiagen-purified MVA-BAC DNA using Lipofectamine
2000 (Invitrogen) in Optimem. The BAC DNA was stored at 4uC,
was never vortexed, and was pipetted only with cut-off tips. The
cells were monitored for GFP expression by epifluorescence
microscopy and were harvested by freeze-thaw 4–6 days later. The
Figure 1. Schematic of construct for recombination into deletion III locus of MVA, based on pBELO-BAC11. DIIIL and DIIIR=left and
right flanks for homologous recombination into MVA genome; GFP=green fluorescent protein gene; p4B=Fowlpox virus late promoter;
CmR=chloramphenicol acetyltransferase gene for selection in E. coli. Flanking FseI sites are absent from MVA and permit excision of the cassette. The
PacI site is provided for linearisation of the plasmid prior to recombination with MVA in infected transfected cells.
doi:10.1371/journal.pone.0001638.g001
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cultures were monitored for the appearance of virus growth.
Rescued viruses were amplified in BHK cells using DMEM
without serum for infection and growth, before purification over
sucrose cushions and titration on CEFs.
BAC recombineering
GalK-based recombineering was done exactly as described by S.
Warming et al. [55], from whom the reagents and strains were
obtained (see also http://recombineering.ncifcrf.gov/). Sequenc-
ing of PCR products and primer synthesis was performed by
MWG-Biotech AG.
Mouse immunogenicity
Female BALB/c and C57BL/6 mice aged 6 to 8 weeks were
obtained from the Biomedical Services Unit, Oxford University
and procedures were conducted according to the UK Animals
(Scientific Procedures) Act 1986. Mice were anaesthetised with
ketamine-dormitor prior to intradermal immunisation with
10
6 pfu of MVA divided into two 25 ml injections (one per ear).
Splenocytes were harvested as described [58] seven days post-
immunisation for flow cytometric analysis or fourteen days post-
immunisation for ELIspot analysis. ELIspots were conducted using
18–20 h stimulation with 1 mg/mL synthetic peptide (ProIm-
mune) in IVPH plates (Millipore) coated with anti-IFN-c antibody
AN18 (Mabtech). Spots were developed with R46A2-biotin
(Mabtech) followed by streptavidin alkaline phosphatase (Mab-
tech) and substrate kit (BioRad) and enumerated on an automated
reader (Autoimmun Diagnostika). For flow cytometry, cells were
stimulated for 6h with 1 mg/mL peptide in the presence of 2 ml/
mL Golgi-Plug (BD) and stained with anti-CD8 pacific blue
conjugate and anti-CD4 APC-Alexa-750 conjugate prior to
fixation in 10% neutral buffered formalin (Sigma). Intracellular
cytokine staining was performed using FITC-conjugated anti
TNF-a, PE-conjugated anti-IL-2 and Alexa-647-conjugated anti-
IFN-c diluted in Cytoperm (BD). All antibodies were obtained
from eBiosciences. Data were acquired on a CyAn flow cytometer
(Dako) and analysed using FlowJo (Treestar). PESTLE and SPICE
software were obtained from Dr M. Roederer, Vaccine Research
Centre, NIH. Other statistical analyses were performed using
Prism (GraphPad Software, Inc.).
Results
Cloning of MVA genome into BAC
A procedure very similar to that developed by Domi and Moss for
VAC-BAC [53] was used to create BACs containing the genome of
MVA. First, a cassette containing pBELO-BAC11, a LoxP
recombinase site and a GFP reporter gene driven by a late poxviral
promoter (see Figure 1) was inserted into the deletion III locus of
MVA by conventional recombination in infected CEF cells. Cells
infected with this recombinant virus, referred to at MVA-BAC-
parent, were treated with isatin-b-thiosemicarbazone (IbT) to inhibit
viral hairpin resolution and promote genome concatemerisation
[59]. After transformation of E. coli with DNA from these cells,
dozens of chloramphenicol-resistant colonies were observed regard-
less of treatment of infected cells with IbT. Unexpectedly,
transfection of cells with pCI-Cre prior to infection in an attempt
to induce recombination between LoxP sites to produce circular
molecules from head-to-tail concatemers [53] dramatically de-
creased the number of colonies obtained, probably due to
cytotoxicity of the transfection reagent. Alternatively, it is possible
that cryptic LoxP sites such as those present in mammalian genomes
[60] resulted in illegitimate recombination events.
Colonies were screened for potential full-length clones by PCR
at five loci spaced along the genome, and candidates were further
characterised by restriction mapping with HindIII and XhoI and
pulsed-field gel electrophoresis after digestion with FseI to excise
the BAC cassette (data not shown). No full-length clones were
isolated from pCI-Cre transfected samples (of 5 colonies screened),
but from untransfected cells, four apparently full-length clones
were obtained, three derived from IbT-treated cells (of 24 colonies
screened) and one from untreated cells (of 18 colonies screened).
This frequency is very similar to that observed for VAC-BAC [53].
BAC rescue
The next step was to ‘‘rescue’’ the BAC clones to infectious MVA
using a Fowlpox virus helper to provide transcriptional machinery.
The BHK cell line, which is the only mammalian cell line known to
support MVA replication, is ideal for this purpose since it is non-
permissive for the host-range restricted avipoxviruses. Following
transfection into BHK cells infected with Fowlpox virus, all four of
the MVA-BAC clones were converted to infectious MVA able to
replicate and form plaques on BHK and CEF cells. We have not
conducted formal growth rate analysis of the resulting viruses, but
viral titres of 8.0610
8 to 2.4610
9 pfu/mL (final volume ,0.5 mL)
were achieved following sucrose cushion purification from BHK
cultures totalling 1500 cm
2. The titrations were performed on CEF
cells,inwhich Fowlpoxvirus canreplicate, andabsenceofsignificant
residual Fowlpox virus was demonstrated by X-Gal staining for the
LacZ marker gene present in the helper virus.
Immunogenicity of MVA-BACs
The principal utility of MVA is as a vaccine vector, particularly
for eliciting T cell responses. The immunogenicity of the viruses
derived from the four MVA-BAC clones was therefore assessed in
mice by determining CD8
+ T cell responses to viral antigens
following intradermal inoculation. Tscharke et al. have described
in detail the immunodominance hierarchy of CD8
+ T cell
‘‘determinants’’ (i.e., epitopes) following infection of BALB/c
and C57BL/6 mice with Vaccinia virus, MVA and other
poxviruses [61,62]. We used the described synthetic peptides to
stimulate splenocytes from immunised BALB/c or C57BL/6 mice
and quantified antigen-specific T cell responses by IFN-c ELIspot
assay (Figure 2).
Mice were immunised intradermally with the four MVA-BAC
clones, the MVA-BAC-parent (from which the BAC clones were
derived), or MVA (i.e. virus lacking the BAC cassette). In C57BL/
6 mice, all were immunogenic and there was no statistically
significant difference by one-way ANoVA between the T cell
responses to any of these viruses for each of the five available
determinants. In BALB/c mice, the same was true for the
immunodominant determinant E3, but there were significant
differences in the subdominant determinant specific F2(G)
responses (p,0.01, one-way ANoVA), and a post-hoc test revealed
that the statistically significant pairwise comparisons are clone
#26 versus parent or MVA (p,0.05, Newman-Keuls multiple
comparison test). Despite the lack of conventional significance for
other clones, there is a trend towards higher responses to BAC-
derived MVA in BALB/c mice, but this is not an effect of the
presence of the BAC cassette at deletion III, since MVA-BAC-
parent also contains this insertion.
The inability to distinguish the MVA-BAC clones by restriction
map, viral growth yield or murine immunogenicity suggests that
they are likely to be identical, but the possibility of some bias in the
isolation procedure necessitates verification of clone fidelity by
complete sequencing, especially prior to embarking on a
programme of genetic manipulation.
MVA-BAC Recombineering
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Three MVA genome sequences are available in GenBank, one
published by Antoine et al. [5] (U94848), one deposited by
Bavarian Nordic GmbH (DQ983236) and the ‘‘Acambis 3000’’
strain (AY603355) deposited by the CDC. The Bavarian Nordic
sequence is identical to the Acambis sequence, and these differ
from Antoine et al.’s sequence only by five single nucleotide
substitutions (excluding the repeat regions of the inverted terminal
repeats, which are not fully described in the Acambis and Bavarian
Nordic sequences). All of these loci are very polymorphic amongst
strains of Vaccinia virus (http://www.poxvirus.org/). The muta-
tions and genes affected are shown in Table 1.
MVA-BAC clone #26 was selected for shotgun sequencing at
eightfold coverage, resulting in a single contig (excluding the
repeat regions), and was found to be identical to the Acambis/
Bavarian Nordic strain, with the exception of a 6 bp insertion in
the non-essential gene F7L [63]. The mutation codes for an extra
Asn-Lys repeat and makes MVA-BAC identical to the TanTien
strain of Vaccinia virus at this polymorphic locus, where other
strains have two Asn-Lys repeats, with the exception of the
Copenhagen strain which has eight (http://www.poxvirus.org/).
In order to determine at what point in the genesis of MVA-BAC
this mutation occurred, we sequenced the progenitor viruses at this
locus by PCR amplification from genomic DNA. MVA-BAC-
parent was found to possess the 6 bp insertion mutation, but its
progenitor (from which the recombinant was derived) did not.
Sequencing of PCR products revealed that a selection of other
MVA recombinants from our laboratory and our original stock
provided by Anton Mayr did not possess the mutation. It is not
clear whether this 6 bp insertion arose during production of the
MVA-BAC parent, or represents isolation of a rare genotype
present at low levels in the source MVA. Evidence for genetic
heterogeneity within poxvirus strains [64,65](personal communi-
cation, R. Regnery) favours the latter possibility.
Deletion of MVA genes by BAC recombineering
Recombination mediated genetic engineering (recombineering)
permits modification of BAC DNA by homologous recombination
in E. coli. We used the system described by Warming et al. [55],
which is based on stringent temperature-sensitive expression of the
l Red genes exo, bet and gam coupled with GalK-based positive and
negative selection. A similar approach, not using GalK, has been
described for VAC-BAC by Domi and Moss [54], who also
verified the stability of their Vaccinia virus BAC clone after
induction of the l Red system. Five genes reported to affect MVA
immunogenicity or Vaccinia virus immunogenicity or virulence
were selected from the literature for deletion by insertion of GalK
in place of the ORF (see Table 2). Long oligonucleotide primers
Figure 2. Immunogenicity of four MVA-BAC clones (21, 22, 26, 48) in C57BL/6 and BALB/c mice compared to parent virus
(containing the BAC cassette) and MVA (lacking the BAC cassette). Mice were immunised with 10
6 pfu i.d. and the specific T cell responses
to the indicated endogenous synthetic peptide epitopes [61,62] were measured 14 days later by IFN-c ELIspot assay. Data are means and SEM from
groups of four mice.
doi:10.1371/journal.pone.0001638.g002
Table 1. Polymorphisms in MVA and MVA-BAC clone #26.
Position
a Gene affected Mutation Coding change MVA strains possessing mutation
b
Example Vaccinia virus strain
possessing mutation
c
68740 G6R A.GN .D A/BN, MVA-BAC Lister, WR, TAN
73886 L3L C.TR .K A/BN, MVA-BAC WR
108489 A4L C.T Silent A/BN, MVA-BAC WR
114308 A10L T.C Silent A/BN, MVA-BAC WR
114945 A10L C.TR .K A/BN, MVA-BAC Lister
30326 F7L 6 bp ins. NK ins. MVA-BAC TAN
aRefers to residue numbering of MVA genome sequence U94848 [5].
bA/BN=Acambis/Bavarian Nordic (see text).
cWR=Western Reserve; COP=Copenhagen; TAN=TanTien.
doi:10.1371/journal.pone.0001638.t001
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of GalK by PCR and these products were electroporated into heat-
induced SW102 cells carrying MVA-BAC prior to selection on
galactose minimal medium, as described [55]. Before rescue by
transfection into Fowlpox virus infected BHK cells, as above, the
modified BACs were checked by restriction digest with HindIII and
XhoI and by sequencing two PCR products spanning the junctions at
the GalK insertion. In only one case (the A46R deletion), was any
mutation detected: a primer-derived single nucleotide deletion in the
intergenic region downstream of the insertion. This mutation was
ignored as it did not fall within any predicted regulatory sequences
(promoters or terminators). GalK deletion mutant BACs were also
checked for absence of undeleted contaminants by PCR across the
deletedlocus.All fivemodifiedGalK-carrying MVA-BACsconverted
into infectious virus, and again, though we did not formally compare
growth rates, all were amplified to titres of 2.8610
8 to 2.6610
9 pfu/
mL (final volume ,0.5 mL) following sucrose cushion purification
from 1500 cm
2 of BHKs.
Immunogenicity of MVA-BAC deletion mutants
The effect of the above modifications on immunogenicity was
assessed in intradermally immunised BALB/c mice. Peak specific
T cell responses were analysed seven days later by flow cytometry
with intracellular cytokine staining following stimulation with the
F2(G) and E3 peptides (Figure 3). No statistically significant
differences between groups were observed (one-way ANoVA for
each epitope). Of the selected genes, only B15R, which encodes an
IL-1b-binding protein, has been reported to affect MVA immuno-
genicity, rather than Vaccinia virus immunogenicity or virulence
[51]. At the peak of the response, Staib et al. described a small non-
significant effect of B15R deletion, very similar to that shown in
Figure 3 for the E3 epitope, and with an identical p-value by t-test
(p=0.07); however, in the memory phase six months post-
vaccination, they observed a highly significant ,4.5-fold increase
in CD8
+ Tc e l lr e s p o n s et ot h eB15R deletion mutant. We therefore
assessed memory responses at 8 weeks post-vaccination, and
observed a small, but statistically significant increase in CD8
+ T
cellresponses to E3(p=0.039, t-test), but not to F2(G). As well as the
readout time, variation in dose (10
8 vs. 10
6 pfu), route (i.p. vs. i.d.),
antigen(H3 vs. E3peptide)and mouse strain(HHDvs. BALB/c) are
likely to underlie the suggested difference in the magnitude of the
effect of B15R deletion on memory T cell responses.
In order to characterise the effect of B15R deletion further, we
analysed E3-specific CD8
+ T cell expression of TNF-a and IL-2 in
addition to IFN-c. SPICE software [66] was used to discriminate
individual cells expressing the seven different ‘Boolean’ combina-
tions of cytokines from the IFN-c
+, TNF-a
+ and IL-2
+ gated
populations (Figure 4). This approach reveals that at the peak of
the response (d7), most of the cells are IFN-c and TNF-a double-
positives. Furthermore, although there is no conventionally
significant difference, the increase in bulk IFN-c responses
observed with the B15R deletion mutant is primarily the result
of an increased number of these double-positive cells, rather than
of the IFN-c single-positive or the IFN-c, TNF-a and IL-2 triple-
positive cells that account for the remainder of the CD8
+ T cell
response. By contrast, at day 56, the effect of B15R deletion is seen
to reside mainly within the triple-positive population, and the
difference is statistically significant (p=0.018, Willcoxon-Rank
test). Deletion of B15R therefore affects both the quality and
magnitude of the E3-specific CD8
+ T cell response to MVA.
Enhanced production of the mitogenic cytokine IL-2 during the
early memory phase (8 weeks) may underpin the large difference in
T cell frequency observed in Staib et al.’s 6 month experiment [51].
Insertion of a recombinant antigen into MVA by BAC
recombineering
In addition to more rapid production of deletion mutants, the
MVA-BAC system would also have value as a faster method for
insertion of genes encoding exogenous protective antigens or
candidate ‘molecular adjuvants’ with the potential to increase vector
immunogenicity. The elegance of the GalK based recombineering
system [55] relies on the ability to counterselect for clones lacking
GalK using deoxygalactose, which is metabolised to a toxic
Table 2. MVA-BAC genes deleted by GalK recombineering.
Gene Function of encoded protein Refs Left homology arm (bp)
a Right homology arm (bp)
a Mutations in MVA
b
C12L IL-18 binding protein [41,42] 13195-13224 13415-13464 6 bp in-frame deletion
A44L Hydroxysteroid dehydrogenase [44,45] 142608-142657 143549-143598 1 amino acid substitution
A46R Inhibitor of Toll-like receptor signalling [46] 143941-143990 144699-144748 –
B7R Chemokine binding protein (SCP-3
c) [36] 156989-157038 157564-157613 15 bp in-frame deletion
B15R IL-1b binding protein [51] 161971-162020 162999-163048 –
aRefers to residue numbering of MVA genome sequence U94848 [5].
bCoding mutations specific to MVA, i.e. not known in any other strain of Vaccinia virus.
cSmallpox virus encoded chemokine receptor (SECRET) domain containing protein 3.
doi:10.1371/journal.pone.0001638.t002
Figure 3. Peptide-specific splenic CD8
+ T cell responses 7 days
(d7) or 56 days (d56) after i.d. immunisation of BALB/c mice
with 10
6 pfu of MVA-BAC derived viruses, either unmodified
or with indicated genes deleted by insertion of GalK. * p=0.039
(t-test). Data are means and SEM from groups of four mice.
doi:10.1371/journal.pone.0001638.g003
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selectable marker. However, loss of GalK can occur both by
recombination with an electroporated DNA, or by deletion of a
segment of the BAC. Unlike GalK insertion, which has an efficiency
close to 100% in MVA-BAC, the specific replacement of GalK with
an exogenous sequence has been achieved to date at a frequency of
only up to 1% compared to spontaneous deletions.
We used this technique to insert an antigen expression cassette
carrying no tandem reporter gene or selectable marker into the
traditional thymidine kinase (TK) locus of MVA-BAC. This
construct comprised the p7.5 early/late promoter driving an 82
amino acid epitope string, named ‘‘TIP’’ (for Tuberculosis,
Immunodeficiency virus and Plasmodium), which contains
relevant epitopes from various pathogens for vaccine-induced
protection in mouse models, including the protective H-2K
d-
restricted Pb9 epitope from Plasmodium berghei circumsporozoite
protein [67]. Figure 5 shows that Pb9-specific CD8
+ T cell
responses are elicited in MVA-BAC-TIP immunised mice to a
level comparable with those elicited by conventional MVA-TIP.
Although not statistically significant, there is a trend toward higher
Pb9 responses (p=0.07, t-test) and lower E3 responses (p=0.11, t-
test) in the conventionally derived MVA-TIP compared to the
BAC-derived virus. This difference in immunodominance hierar-
chy may be attributable to differences in the nature of the cassette
inserted at the TK locus (the lack of a late-promoter-driven GFP
marker gene and opposite orientation of the TIP gene) or to the
presence of the BAC cassette at deletion III.
Discussion
Traditional methods for genetic manipulation of poxviruses,
either for mutagenesis or expression of exogenous genes, rely on
onerous plaque purification of rare recombinant viruses. Building
on the results of Domi and Moss for VAC-BAC [53,54], here we
circumvent this requirement by creating an MVA-BAC that can
be manipulated using recombineering and rescued to clonal
Figure 4. Multifunctionality of CD8
+ T cells induced 7 days (d7) or 56 days (d56) after immunisation of BALB/c mice with
unmodified MVA-BAC or B15R deletion mutant. Histograms show frequency of cells expressing each of the seven possible combinations of IFN-
c, IL-2 and TNF-a with bars showing the mean and circles showing the values for individual mice (n=4). Pie charts show fraction of the total response
comprised of cells expressing all three cytokines (black), any two cytokines (dark gray), or one cytokine only (light gray). * p=0.018, Willcoxon-Rank
test. Analysis performed using SPICE software [66].
doi:10.1371/journal.pone.0001638.g004
Figure 5. Immunogenicity of MVA-BAC expressing a recombi-
nant antigen inserted at the standard thymidine kinase
insertion site, in comparison to conventional recombinant
MVA and recombineering precursors containing no insertion
or GalK. The recombinant antigen, TIP, is an epitope string containing
the Pb9 epitope from Plasmodium berghei circumsporozoite protein
[67]. Bars show mean specific CD8
+ T cell responses to the indicated
peptides 7 days after i.d. vaccination of with 10
6 pfu, from groups of
four BALB/c mice, with error bars showing SEM.
doi:10.1371/journal.pone.0001638.g005
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VAC-BAC, we generated four MVA-BAC clones, which were
identical by restriction map and had indistinguishable CD8
+ T cell
immunogenicity in two strains of mice. We sequenced one clone,
and found it to be identical to published genomic sequences of
MVA, with the exception of a minor mutation that is polymorphic
amongst Vaccinia virus strains and was present in the parent
MVA recombinant. We did not conduct an investigation into
stability of the construct, since good stability had been shown for
the even larger VAC-BAC construct [53,54].
Of five candidate genes selected from the literature for deletion by
MVA-BAC recombineering (Table 2), only one had any statistically
significant effect on responses to viral CD8
+ Tc e l le p i t o p e sf o l l o w i n g
intradermal immunisation of BALB/c mice. The effect of B15R
deletion was morepronounced 8 weeks post-vaccination, though not
as great as was previously reported at a 6 month timepoint in HHD
mice [51]. Although we did not observe an effect of similar
magnitude using an earlier readout, we show using SPICE
polychromatic flow cytometry analysis that antigen-specific CD8
+
TcellsfrommiceimmunisedwithMVAlackingB15Rarecomposed
of a higher proportion of triple-positive cells that express IL-2 in
addition to IFN-c and TNF-a. This ‘multi-functional’ phenotype
may be responsible for the large differences in cell frequency at 6-
months post-vaccination [51], since IL-2 is strongly implicated in
memory T cell homeostasis [68] and its expression by virus-specific
CD8
+ T cells has been reported to promote antigen-specific
proliferation of these cells even in the absence of CD4
+ Tc e l lh e l p
[69]. Whether responses to a recombinant antigen will be
augmented in a B15R deletion background remains to be tested,
though it should be noted in this regard that enhancement of anti-
vector responses was confined to the E3-specific response and was
not observed in the case of the F2(G) epitope.
Deletion of four other genes by GalK insertion in MVA-BAC did
not potentiate CD8
+ T cell responses to the vector epitopes. C12L,
A44Rand B7RallcarryMVA-specificmutationsthatdonotoccurin
any other sequenced strain of Vaccinia virus. Although strain
Ankara (from which MVA was derived) has not been sequenced,
these mutations presumably arose during attenuation, and the genes
affected may therefore already be inactive. Alternatively, or
additionally, functional redundancy of families of immunomodula-
tory genes acting on the same pathways may negate the effect of the
deletion mutants. Indeed, poxviruses appear to have taken a
grapeshot-like approach to disruption of the TLR/IL-1R signalling
pathway [6], though MVA’s gun has been spiked by deletion of
manycomponents, including A52R, which like A46Rcan inhibit NF-
kB activation, albeit by a distinct subset of stimuli [46].
The deletion of these genes also did not impair the CD8
+ Tc e l l
responses to the vector, suggesting that, as well as being dispensable
for growth in BHK cell culture, they are not required for
circumvention of host defence mechanisms operating in vivo (though
since MVA is non-replicating in mammals, this conclusion does not
extend to poxviral pathogenesis). If multiple MVA genes were to be
deleted, in order to overcome putative functional redundancy, one
might assume that at some point the virus would be so crippled as to
be only very poorly immunogenic, for example by an antiviral
response occurring early during the infection cycle, which normally
proceeds to immature virion formation even in non-permissive cells.
On the other hand, the major evolutionary driving force for
acquisition of immunomodulators by poxviruses is more likely
productive replication of a virulent virus, rather than evasion of
adaptive responses (i.e. antibody or cytotoxic T cell responses). The
MVA-BAC recombineering system will hopefully be versatile and
rapid enough to allow these subtleties to be addressed, especially as it
is likely to speed up the production of ‘revertant’ viruses in order to
confirm the genetic specificity of a novel phenotype. Furthermore,
the ability to make multiple modifications by ‘recycling’ the GalK
dual-selectable marker is likely to be of particular value.
Other applications of MVA-BAC include production of viruses
carrying recombinant antigens and/or molecular adjuvants for
pre-clinical evaluation and clinical trial. The use of BAC DNA and
an inactivated clinical grade helper virus as the input to a
manufacturing process could reduce the burden of traceability
currently required by regulatory authorities, though a method for
efficient removal of the BAC cassette would be needed (see
Figure 1). In this setting, the issues of construct stability and helper
virus contamination would doubtless require more rigorous
investigation than described here. Insertion of antigen expression
cassettes by recombineering additionally circumvents the require-
ment for a reporter gene or selectable marker and its removal by
transient-dominant selection [70] when a markerless product is
required. In this regard, the difficulty of insertion of the TIP
antigen by GalK counterselection is rather disappointing, though
there is very likely room for improvement, for example by using
longer homology arms in the targeting DNA, or electroporating
maximal quantities of DNA. When removing GalK without
concomitant insertion of DNA (i.e., from a deletion locus), we
have achieved much higher recombineering efficiencies of up to
95% (data not shown). Alternatively, recombination in RecA
+ E.
coli [71] is a potential means of inserting elements without the use
of a selectable marker, since several rare restriction sites (required
for linearisation of the BAC prior to recombination) are absent
from the MVA genome. For pre-clinical work, an in vitro site
specific recombination system could be developed [72].
The vaccine vector capability of Vaccinia virus expressing a
recombinant antigen was demonstrated nearly 25 years ago
[73,74]. Successful vectored vaccines for diseases such as malaria,
HIV-AIDS and tuberculosis will likely require combinations of
antigens and delivery systems able to induce immune responses of
the right character and magnitude against the recombinant
antigens. Currently, MVA is one of the more promising
deployable delivery systems and has potential for improvement.
The MVA-BAC technology provides an opportunity to accelerate
production of candidate vaccines for evaluation, and potentially a
superior starting point for clinical vaccine manufacture.
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